1116 related articles for article (PubMed ID: 22452448)
1. Cost effectiveness of prostacyclins in pulmonary arterial hypertension.
Roman A; Barberà JA; Escribano P; Sala ML; Febrer L; Oyagüez I; Sabater E; Casado MA
Appl Health Econ Health Policy; 2012 May; 10(3):175-88. PubMed ID: 22452448
[TBL] [Abstract][Full Text] [Related]
2. Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation.
Chen YF; Jowett S; Barton P; Malottki K; Hyde C; Gibbs JS; Pepke-Zaba J; Fry-Smith A; Roberts J; Moore D
Health Technol Assess; 2009 Oct; 13(49):1-320. PubMed ID: 19863849
[TBL] [Abstract][Full Text] [Related]
3. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial.
McLaughlin VV; Benza RL; Rubin LJ; Channick RN; Voswinckel R; Tapson VF; Robbins IM; Olschewski H; Rubenfire M; Seeger W
J Am Coll Cardiol; 2010 May; 55(18):1915-22. PubMed ID: 20430262
[TBL] [Abstract][Full Text] [Related]
4. Prostanoid therapy for pulmonary arterial hypertension.
Badesch DB; McLaughlin VV; Delcroix M; Vizza CD; Olschewski H; Sitbon O; Barst RJ
J Am Coll Cardiol; 2004 Jun; 43(12 Suppl S):56S-61S. PubMed ID: 15194179
[TBL] [Abstract][Full Text] [Related]
5. The potential for inhaled treprostinil in the treatment of pulmonary arterial hypertension.
Gessler T; Seeger W; Schmehl T
Ther Adv Respir Dis; 2011 Jun; 5(3):195-206. PubMed ID: 21300738
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of transition from subcutaneous treprostinil to oral sildenafil in patients with pulmonary arterial hypertension.
Keogh AM; Jabbour A; Weintraub R; Brown K; Hayward CS; Macdonald PS
J Heart Lung Transplant; 2007 Nov; 26(11):1079-83. PubMed ID: 18022071
[TBL] [Abstract][Full Text] [Related]
7. The cost effectiveness and cost utility of valsartan in chronic heart failure therapy in Italy: a probabilistic markov model.
Pradelli L; Iannazzo S; Zaniolo O
Am J Cardiovasc Drugs; 2009; 9(6):383-92. PubMed ID: 19929036
[TBL] [Abstract][Full Text] [Related]
8. Prostacyclin therapy for pulmonary arterial hypertension: new directions.
Gomberg-Maitland M; Preston IR
Semin Respir Crit Care Med; 2005 Aug; 26(4):394-401. PubMed ID: 16121316
[TBL] [Abstract][Full Text] [Related]
9. Treatment of pulmonary arterial hypertension: a preliminary decision analysis.
Highland KB; Strange C; Mazur J; Simpson KN
Chest; 2003 Dec; 124(6):2087-92. PubMed ID: 14665484
[TBL] [Abstract][Full Text] [Related]
10. [Economic analysis of rituximab in combination with cyclophosphamide, vincristine and prednisolone in the treatment of patients with advanced follicular lymphoma in Portugal].
Braga P; Carvalho S; Gomes M; Guerra L; Lúcio P; Marques H; Negreiro F; Pereira C; Silva C; Teixeira A
Acta Med Port; 2010; 23(6):1025-34. PubMed ID: 21627880
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of treprostinil versus epoprostenol in patients with pulmonary arterial hypertension: a Canadian analysis.
Einarson TR; Granton JT; Vicente C; Walker J; Engel G; Iskedjian M
Can Respir J; 2005; 12(8):419-25. PubMed ID: 16331313
[TBL] [Abstract][Full Text] [Related]
12. Pulmonary arterial hypertension: new insights into the optimal role of current and emerging prostacyclin therapies.
Waxman AB; Zamanian RT
Am J Cardiol; 2013 Mar; 111(5 Suppl):1A-16A; quiz 17A-19A. PubMed ID: 23414683
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of tapentadol in severe chronic pain in Spain: a cost analysis of data from RCTs.
Obradovic M; Ikenberg R; Hertel N; Antoñanzas F; Gálvez R; Liedgens H
Clin Ther; 2012 Apr; 34(4):926-43. PubMed ID: 22417717
[TBL] [Abstract][Full Text] [Related]
14. Inhaled treprostinil sodium for the treatment of pulmonary arterial hypertension.
Ferrantino M; White RJ
Expert Opin Pharmacother; 2011 Nov; 12(16):2583-93. PubMed ID: 21988216
[TBL] [Abstract][Full Text] [Related]
15. Cost-minimization analysis of treprostinil vs. epoprostenol as an alternate to oral therapy non-responders for the treatment of pulmonary arterial hypertension.
Narine L; Hague LK; Walker JH; Vicente C; Schilz R; Desjardins O; Einarson TR; Iskedjian M
Curr Med Res Opin; 2005 Dec; 21(12):2007-16. PubMed ID: 16368052
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of transition from systemic prostanoids to inhaled treprostinil in pulmonary arterial hypertension.
de Jesus Perez VA; Rosenzweig E; Rubin LJ; Poch D; Bajwa A; Park M; Jain M; Bourge RC; Kudelko K; Spiekerkoetter E; Liu J; Hsi A; Zamanian RT
Am J Cardiol; 2012 Nov; 110(10):1546-50. PubMed ID: 22853986
[TBL] [Abstract][Full Text] [Related]
17. [Role of prostacyclin and its derivatives in the treatment of pulmonary arterial hypertension].
Osvaldo Cáneva J; Ossés JM
Medicina (B Aires); 2003; 63(3):233-6. PubMed ID: 12876911
[TBL] [Abstract][Full Text] [Related]
18. [Therapy of severe pulmonary hypertension with prostacyclin and iloprost].
Matthes J; Mathen F; Herzig S; Wassermann K
Dtsch Med Wochenschr; 2001 May; 126(21):631-7. PubMed ID: 11413752
[No Abstract] [Full Text] [Related]
19. Rapid switch from intravenous epoprostenol to intravenous treprostinil in patients with pulmonary arterial hypertension.
Sitbon O; Manes A; Jais X; Pallazini M; Humbert M; Presotto L; Paillette Ld; Zaccardelli D; Davis G; Jeffs R; Simonneau G; Galie N
J Cardiovasc Pharmacol; 2007 Jan; 49(1):1-5. PubMed ID: 17261956
[TBL] [Abstract][Full Text] [Related]
20. Transition from intravenous or subcutaneous prostacyclin therapy to inhaled treprostinil in patients with pulmonary arterial hypertension: a retrospective case series.
Enderby CY; Soukup M; Al Omari M; Zeiger T; Burger C
J Clin Pharm Ther; 2014 Oct; 39(5):496-500. PubMed ID: 24806480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
